185 related articles for article (PubMed ID: 33409897)
1. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Miura A; Sootome H; Fujita N; Suzuki T; Fukushima H; Mizuarai S; Masuko N; Ito K; Hashimoto A; Uto Y; Sugimoto T; Takahashi H; Mitsuya M; Hirai H
Invest New Drugs; 2021 Jun; 39(3):724-735. PubMed ID: 33409897
[TBL] [Abstract][Full Text] [Related]
2. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
3. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins.
Chi YH; Yeh TK; Ke YY; Lin WH; Tsai CH; Wang WP; Chen YT; Su YC; Wang PC; Chen YF; Wu ZW; Yeh JY; Hung MC; Wu MH; Wang JY; Chen CP; Song JS; Shih C; Chen CT; Chang CP
J Med Chem; 2021 Jun; 64(11):7312-7330. PubMed ID: 34009981
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
[TBL] [Abstract][Full Text] [Related]
6. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
[TBL] [Abstract][Full Text] [Related]
7. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
8. Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways.
Zhang C; Wu X; Zhang M; Zhu L; Zhao R; Xu D; Lin Z; Liang C; Chen T; Chen L; Ren Y; Zhang J; Qin N; Zhang X
PLoS One; 2013; 8(6):e65264. PubMed ID: 23755206
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
10. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
[TBL] [Abstract][Full Text] [Related]
11. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
[TBL] [Abstract][Full Text] [Related]
12. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
[TBL] [Abstract][Full Text] [Related]
15. Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes
Sootome H; Miura A; Masuko N; Suzuki T; Uto Y; Hirai H
Mol Cancer Ther; 2020 Oct; 19(10):1981-1991. PubMed ID: 32788206
[TBL] [Abstract][Full Text] [Related]
16. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
[TBL] [Abstract][Full Text] [Related]
18. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
19. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
[No Abstract] [Full Text] [Related]
20. Aurora kinase A is a possible target of OSU‑03012 to destabilize MYC family proteins.
Silva A; Wang J; Lomahan S; Tran TA; Grenlin L; Suganami A; Tamura Y; Ikegaki N
Oncol Rep; 2014 Sep; 32(3):901-5. PubMed ID: 25017515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]